Literature DB >> 12823206

Response to preoperative chemotherapy affects prognosis in esophageal cancer.

M Miyashita1, T Tajiri, K Sasajima, H Makino, H Maruyama, T Nomura, R Futami, N Hagiwara, Y Tsuchiya, K Yamashita.   

Abstract

The effect of preoperative chemotherapy on prognosis is still controversial. We have investigated the relationship between responses to preoperative chemotherapy and prognosis after curative operations in patients with esophageal squamous cell carcinoma. Thirty-nine patients received preoperative chemotherapy with continuous infusion of 500 mg/m2 of 5-fluorouracil (5-FU) and intravenous injection of 20 mg/m2 of leucovorin every 12 hours for 5 days. On the 5th day alone, 70 mg/m2 of cisplatin was also infused. The effect was evaluated approximately 14 days after the end of one course of chemotherapy. The rates of responders and non-responders were 64.1% and 35.9%, respectively. After an interval of 21-28 days, transthoracic esophagectomy was performed. Significant histological effect by chemotherapy was found in responders compared to non-responders (P < 0.05). Responders had a significantly better prognosis than non-responders by Log-rank test (P < 0.01). This suggests that preoperative chemotherapy may contribute to better prognosis when the tumor is sensitive to chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12823206     DOI: 10.1046/j.1442-2050.2003.00301.x

Source DB:  PubMed          Journal:  Dis Esophagus        ISSN: 1120-8694            Impact factor:   3.429


  5 in total

1.  Peritherapeutic Serum p53 Antibody Titers are Predictors of Survival in Patients with Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemotherapy and Surgery.

Authors:  Kotaro Yamashita; Tomoki Makino; Koji Tanaka; Makoto Yamasaki; Masaaki Yamamoto; Yasuhiro Miyazaki; Tsuyoshi Takahashi; Yukinori Kurokawa; Kiyokazu Nakajima; Shuji Takiguchi; Masaki Mori; Yuichiro Doki
Journal:  World J Surg       Date:  2017-06       Impact factor: 3.352

2.  Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy.

Authors:  Hirotaka Konishi; Hitoshi Fujiwara; Atsushi Shiozaki; Hidekazu Hiramoto; Toshiyuki Kosuga; Shuhei Komatsu; Daisuke Ichikawa; Kazuma Okamoto; Eigo Otsuji
Journal:  Int J Clin Oncol       Date:  2015-07-21       Impact factor: 3.402

3.  The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma.

Authors:  Min-Shu Hsieh; Pei-Wen Yang; Li-Fan Wong; Jang-Ming Lee
Journal:  Oncotarget       Date:  2016-06-14

4.  Visible-absorption spectroscopy as a biomarker to predict treatment response and prognosis of surgically resected esophageal cancer.

Authors:  Pei-Wen Yang; I-Jen Hsu; Chun-Wei Chang; Yu-Chia Wang; Ching-Yueh Hsieh; Kuan-Hui Shih; Li-Fan Wong; Nai-Yu Shih; Min-Shu Hsieh; Max Ti-Kuang Hou; Jang-Ming Lee
Journal:  Sci Rep       Date:  2016-09-14       Impact factor: 4.379

5.  Cabozantinib (XL184) and R428 (BGB324) Inhibit the Growth of Esophageal Squamous Cell Carcinoma (ESCC).

Authors:  Pei-Wen Yang; Yu-Cheng Liu; Ya-Han Chang; Ching-Ching Lin; Pei-Ming Huang; Kuo-Tai Hua; Jang-Ming Lee; Min-Shu Hsieh
Journal:  Front Oncol       Date:  2019-11-06       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.